Aurinia Pharmaceuticals (AUPH) Interest & Investment Income (2020 - 2026)

Aurinia Pharmaceuticals (AUPH) has 6 years of Interest & Investment Income data on file, last reported at $3.5 million in Q1 2026.

• Quarterly Interest & Investment Income fell 1.51% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.5 million (down 15.57% YoY) and the FY2025 annual result came in at $13.6 million, down 20.02% from the prior year.
• Interest & Investment Income held at $3.5 million in Q1 2026, from $3.5 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $4.6 million in Q4 2023 to a low of $3.2 million in Q2 2025.
• A 4-year average of $3.9 million and a median of $4.0 million in 2024 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2025 — Interest & Investment Income decreased 23.85% — and 2026, when it retreated 1.51%.
• Tracing AUPH's Interest & Investment Income over 4 years: stood at $4.6 million in 2023, then fell by 12.7% to $4.0 million in 2024, then slipped by 12.29% to $3.5 million in 2025, then climbed by 0.49% to $3.5 million in 2026.
• The last three Interest & Investment Income figures came in at $3.5 million (Q1 2026), $3.5 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.